Cell and Gene Therapy Catapult’s Annual Review 2021
- Published on 22nd November 2021 by Cell and Gene Therapy Catapult
The past year emphasised the strength and world-leading capabilities of the UK cell and gene therapy industry which experienced significant expansion despite the COVID-19 pandemic.
The Cell and Gene Therapy Catapult has published its 2021 Annual Review, highlighting that the UK has become a place of choice to set up advanced therapy medicinal products (ATMP) activities, with 29% of European ATMP companies operating in the country.
Click here to read the Cell and Gene Therapy Catapult’s Annual Review 2021.
Other news
-
GenScript Named a BioSpace 2024 Best Place to WorkPublished on 1 Dec 2023 -
New UK-India research project trialling easy-to-use test to help fight against global threat of antimicrobial resistancePublished on 30 Nov 2023 -
Advanced Therapies Integrates comes to Stevenage – the home of cell and gene therapiesPublished on 30 Nov 2023 -
Leading industry surveys demonstrate continued growth in the UK’s cell and gene therapy sectorPublished on 24 Nov 2023
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.